Latest Developments in Global Dapagliflozin Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Dapagliflozin Market

  • Pharmaceutical
  • Upcoming Report
  • Dec 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In December 2024, Torrent Pharmaceuticals has announced an agreement to acquire three anti-diabetes brands from Boehringer Ingelheim International GmbH (BI). This acquisition will enable Torrent to enhance its portfolio in the diabetes care market, allowing the company to broaden its therapeutic offerings and expand its reach in a rapidly growing global market
  • In November 2024, Adalvo has received early European approval for Dapagliflozin film-coated tablets under the DCP process, ahead of the standard 210-day timeline, enabling a Day-1 launch. This early approval allows the company to gain a competitive advantage and accelerate market entry, enhancing its position in the European market
  • In June 2024, the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) for improving glycemic control in pediatric patients aged 10 years and older with type-2 diabetes (T2D). This approval expands Farxiga's market potential, allowing the company to target a younger patient demographic and strengthen its position in the growing pediatric diabetes treatment market
  • In May 2021, Sun Pharma announced it has acquired the rights to the Dapagliflozin trademarks under the brands Oxra, Oxramet, and Oxraduo in India from AstraZeneca Pharma's parent company. This acquisition strengthens Sun Pharma's diabetes portfolio and expands its market presence in India

Frequently Asked Questions

The market is segmented based on Segmentation, By Indication (Type 2 Diabetes Mellitus, Heart Failure (HFrEF), and Chronic Kidney Disease (CKD)), Dosage Strength (5 mg and 10 mg), Application (Monotherapy and Combination Therapy), Age Group (Adult and Geriatric), End User (Hospitals, Specialty Clinics, and Homecare Settings), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2032 .
The Global Dapagliflozin Market size was valued at USD 3.21 USD Billion in 2024.
The Global Dapagliflozin Market is projected to grow at a CAGR of 6.7% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.